-
A Phase Ib/II Multicenter Open-label Modular Dose-Finding and Dose Expansion Study to Explore the Safety Tolerability and Anti-tumor Activity of Trastuzumab Deruxtecan (DS-8201a T-DXd) in Combination with other Anti-cancer Agents in Patients with Metastatic HER2-positive Breast Cancer (DESTINY-Breast07)
The purpose of the study is to determine if study drug Trastuzumab Deruxtecan (T-DXd) can be given safely in combination with other cancer treatments to ... -
Phase 1 and phase 2a first-in-human study of DRP-104 a glutamine antagonist in adult patients with advanced solid tumors
The purpose of the study is to assess safety, tolerability, and antitumor activity of DRP-104 administered via intravenous infusion as a single agent and in ... -
A Phase 1/2 First-in-Human Open-Label Dose Escalation Study of Talquetamab a Humanized GPRC5D x CD3 Bispecific Antibody in Subjects with Relapsed or Refractory Multiple Myeloma
The purpose of the study is to determine if talquetamab is safe and useful for treating patients with multiple myeloma and to assess how the ... -
An Open-Label Multicenter Non-Randomized Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety Tolerability and Anti-Tumor Activity of ATP128 With or Without BI 754091 in Patients With Stage IV Colorectal Cancer
The purpose of the study is to determine the safety and tolerability of ATP128 alone or in combination with BI 754091. ATP128 is a self-adjuvanted ... -
A Phase 1 b/2 Open-Label Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer
The purpose of the study is to evaluate the antitumor activity and safety/tolerability of etruma-based combination therapy in participants with metastatic colorectal cancer (mCRC ... -
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer
The purpose of the study is to evaluate the safety and tolerability of BLU-945, an orally available, highly potent and selective inhibitor of EGFR resistance ... -
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D
The purpose of the study is to determine the efficacy of investigational agents with or without pembrolizumab for the treatment of PD-1 naïve or PD-1 ... -
A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors
The purpose of the study is to evaluate the safety and tolerability of the study drug CPI-0209 as monotherapy and in combination with irinotecan in ... -
A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
The purpose of the study is to evaluate the safety and efficacy of AVB-S6-500 in combination with nab-paclitaxel and gemcitabine in subjects with locally advanced ... -
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti PD-1) INCAGN02385 (Anti LAG-3) and INCAGN02390 (Anti TIM-3) in Participants With Select Advanced Malignancies
The purpose of the study is to determine safe combination doses and preliminary safety and efficacy for the combination of INCAGN02385, INCAGN02390, and INCMGA00012. INCMGA00012 ...